159326-69-9

Basic information

• Product Name: 1H-Pyrrole-2-carboxamide,1-amino-(9CI)
• Synonyms: 1H-Pyrrole-2-carboxamide,1-amino-(9CI);1-AMINO-1H-PYRROLE-2-CARBOXAMIDE;1-AMino-1H-pyrrole-2-carboxylic acid aMide;1H-Pyrrole-2-carboxamide, 1-amino-;1-aminopyrrole-2-carboxamide
• CAS NO: 159326-69-9
• Molecular Formula: C₅H₇N₃O
• Molecular Weight: 125.13
• Product Categories: AMINEPRIMARY;PYRROLE
• Mol File: 159326-69-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 425.897 °C at 760 mmHg
• Flash Point: 211.375 °C
• Appearance: /
• Density: 1.457 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.659
• Storage Temp.: 2-8°C(protect from light)
• PKA: 16.23±0.50(Predicted)
• CAS DataBase Reference: 1H-Pyrrole-2-carboxamide,1-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-2-carboxamide,1-amino-(9CI)(159326-69-9)
• EPA Substance Registry System: 1H-Pyrrole-2-carboxamide,1-amino-(9CI)(159326-69-9)

Safety Data

• Hazardous Substances Data: 159326-69-9(Hazardous Substances Data)

Usage

General Description

1H-Pyrrole-2-carboxamide, 1-amino-(9CI) is a chemical compound with the molecular formula C5H6N2O. It is an amide derivative of pyrrole, a five-membered aromatic heterocyclic compound. 1H-Pyrrole-2-carboxamide,1-amino-(9CI) is also known as 2-pyrrolecarboxamide and has an amine group attached to the carbon at the 1-position of the pyrrole ring. It has various applications in organic synthesis and pharmaceutical research, including as a building block for the synthesis of other organic compounds and potential drug molecules. Additionally, its unique structure and properties make it a valuable tool for the study of the reactivity and behavior of heterocyclic compounds in chemical reactions.

InChI:InChI=1/C5H7N3O/c6-5(9)4-2-1-3-8(4)7/h1-3H,7H2,(H2,6,9)

Upstream product

• 159326-66-6 N-amino-1H-pyrrole-2-carbonitrile 
• 1003-29-8 2-pyrrole aldehyde 
• 4513-94-4 1H-pyrrole-2-carbonitrile 
• 159326-70-2 1-formylaminopyrrole-2-carboxamide 

Downstream Products

• 159326-70-2 1-formylaminopyrrole-2-carboxamide 
• 159326-73-5 1-<amino>pyrrole-2-carboxamide 
• 1379337-32-2 1-(ethoxyformamido)-1H-pyrrole-2-carboxamide 
• 1008107-47-8 (S)-1-(3-(1-(4-fluoro-phenyl)ethyl)thioureido)-1H-pyrrole-2-carboxamide 
• 773140-19-5 1-(5-chloro-2-fluoro-benzoylamino)-1H-pyrrole-2-carboxylic acid amide 
• 918538-04-2 pyrrolo[2,1-f][1,2,4]triazine-2,4(1H, 3H)-dione 
• 918538-08-6 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 
• 918538-05-3 2,4-dichloro-pyrrolo[2,1-f][1,2,4]triazine 
• 1001353-82-7 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 
• 1001353-78-1 (S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-2-methylpyrrolidine-2-carboxylic acid 

Relevant articles and documents

Heterocyclic amines Hedgehog signal pathway inhibitor

The invention relates to the field of biological medicine, in particular to a heterocyclic amine compound and an application thereof, namely a general formula (I) compound and acceptable salt in the pharmaceutical field. The compound can be used in the Hedgehog signal transduction inhibitor application and various medical applications (please see the formula in the specification). The invention further relates to a preparation method with the general formula (I).

2 - amino-pyrrolo [1, 2 - f] [1, 2, 4] triazine compounds, synthetic method and application

The invention discloses 2-aminopyrrolo[1,2-f][1,2,4]triazine compounds, and a synthesis method and application thereof, particularly 2-aminopyrrolo[1,2-f][1,2,4]triazine compounds, or pharmaceutically acceptable salts, hydrate, solvate or prodrug thereof.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.